研究活動
Research Activities

研究活動
Research Activities

Home › 研究活動 › 主任研究者 › 堀田 秋津 講師

主任研究者
Principal Investigator

臨床応用研究部門 堀田 秋津 講師

発表論文

Ishida K, Xu H, Sasakawa N, Lung MSY, Kudryashev JA, Gee P, Hotta A.

Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells. Scientific Reports., 2018 Jan 10;8:310. doi:10.1038/s41598-017-18568-4.

Kojima Y, Sasaki K, Yokobayashi S, Sakai Y, Nakamura T, Yabuta Y, Nakaki F, Nagaoka S, Woltjen K, Hotta A, Yamamoto T, Saitou M.

Evolutionarily distinctive transcriptional and signaling programs drive human germ cell lineage specification from pluripotent stem cells. Cell Stem Cell., 2017 Oct 5;21(4):517-532.e5. doi: 10.1016/j.stem.2017.09.005.

Chen Z, Chang WY, Etheridge A, Strickfaden H, Jin Z, Palidwor G, Cho JH, Wang K, Kwon SY, Doré C, Raymond A, Hotta A, Ellis J, Kandel RA, Dilworth FJ, Perkins TJ, Hendzel MJ, Galas DJ, Stanford WL.

Reprogramming progeria fibroblasts re-establishes a normal epigenetic landscape. Aging Cell., 2017 Jun 8. doi: 10.1111/acel.12621.

Takada S, Kambe N, Kawasaki Y, Niwa A, Honda-Ozaki F, Kobayashi K, Osawa M, Nagahashi A, Semi K, Hotta A, Asaka I, Yamada Y, Nishikomori R, Heike T, Matsue H, Nakahata T, Saito MK.

Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages. J Allergy Clin Immunol., 2017 Jun 3; pii: S0091-6749(17)30685-1. doi: 10.1016/j.jaci.2017.04.013.

Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo T, Kitaoka S, Ohta A, Tanaka A, Watanabe D, Morita M, Takuma H, Tamaoka A, Kunath T, Wray S, Furuya H, Era T, Makioka K, Okamoto K, Fujisawa T, Nishitoh H, Homma K, Ichijo H, Julien JP, Obata N, Hosokawa M, Akiyama H, Kaneko S, Ayaki T, Ito H, Kaji R, Takahashi R, Yamanaka S, Inoue H.

The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med., 2017 May 24;9(391). pii: eaaf3962. doi: 10.1126/scitranslmed.aaf3962.

Hirosawa M, Fujita Y, Parr CJC, Hayashi K, Kashida S, Hotta A, Woltjen K, Saito H.

Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. Nucleic Acids Res., 2017 May 19. doi: 10.1093/nar/gkx309.

Gee P, Xu H, Hotta A.

Cellular reprogramming, genome Editing, and alternative CRISPR Cas9 technologies for precise gene therapy of Duchenne muscular dystrophy. Stem Cells International., 2017 May 18; Article ID 8765154.

Imamura K, Sahara N, Kanaan NM, Tsukita K, Kondo T, Kutoku Y, Ohsawa Y, Sunada Y, Kawakami K, Hotta A, Yawata S, Watanabe D, Hasegawa M, Trojanowski JQ, Lee VM, Suhara T, Higuchi M, Inoue H.

Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Sci. Rep., 2016 Oct 10;6:34904.

Choi IY, Lim H, Estrellas K, Mula J, Cohen TV, Zhang Y, Donnelly CJ, Richard JP, Kim YJ, Kim H, Kazuki Y, Oshimura M, Li HL, Hotta A, Rothstein J, Maragakis N, Wagner KR, Lee G.

Concordant but varied phenotypes among Duchenne muscular dystrophy patient-specific myoblasts derived using a human iPSC-based model. Cell Rep., 2016 Jun 7;15(10):2301-12.

Komura S, Semi K, Itakura F, Shibata H, Ohno T, Hotta A, Woltjen K, Yamamoto T, Akiyama H, Yamada Y.

An EWS-FLI1-induced osteosarcoma model unveiled a crucial role of impaired osteogenic differentiation on osteosarcoma development. Stem Cell Reports., 2016 Mar 17.

Morita Y, Andersen P, Hotta A, Tsukahara Y, Sasagawa N, Hayashida N, Koga C, Nishikawa M, Saga Y, Evans SM, Koshiba-Takeuchi K, Nishinakamura R, Yoshida Y, Kwon C, Takeuchi JK.

Sall1 transiently marks undifferentiated heart precursors and regulates their fate. J Mol Cell Cardiol., 2016 Feb 11, 92:158-62.

Li HL, Gee P, Ishida K, and Hotta A.

Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system. Methods, 2015 Oct 23, pii: S1046-2023(15)30133-X.

Ishida K*, Gee P*, and Hotta A. (*: equal contribution)

Minimizing off-target mutagenesis risks caused by programmable nucleases. Int. J. Mol. Sci., 2015 Oct 16, 16 (10), 24751-24771

Hotta A, and Yamanaka S.

From genomics to gene therapy: induced pluripotent stem cells meet genome editing. Annu. Rev. Genet., 2015 Sep 25, 49:47-70.

Hotta A.

Genome editing gene therapy for Duchenne muscular dystrophy. J. Neuromuscul. Dis., 2015 Sep 22, 2 (4) 343-355

Ishikawa M, Ohnishi H, Skerleva D, Sakamoto T, Yamamoto N, Hotta A, Ito J, Nakagawa T.

Transplantation of neurons derived from human iPS cells cultured on collagen matrix into guinea-pig cochleae. J Tissue Eng. Regen. Med., 2015 Jul 24.

Iizuka H, Kagoya Y, Kataoka K, Yoshimi A, Miyauchi M, Taoka K, Kumano K, Yamamoto T, Hotta A, Arai S, Kurokawa M.

Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Experimental Hematology, 2015 June 11, 43(10): p849-57.

Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, Yamamoto T, Yamanaka S, and Hotta A.

Precise correction of the Dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports, 2015; Vol.4 (1): p143-154.

Rahmani W, Abbasi S, Hagner A, Raharjo E, Kumar R, Hotta A, Magness S, Metzger D, Biernaskie J.

Hair follicle dermal stem cells regenerate the dermal sheath, repopulate the dermal papilla, and modulate hair type. Dev. Cell, 2014; Vol.31 (5): p543-558

Matsui H, Fujimoto N, Sasakawa N, Ohinata Y, Shima M, Yamanaka S, Sugimoto M, and Hotta A

Delivery of full-length Factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A PLOS ONE, 2014; Vol.9 (8): e104957

Kondo T, Funayama M, Tsukita K, Hotta A Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H, Yamanaka S, and Inoue H

Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports, 2014; Vol.3 (2): p242-249.

Li HL, Nakano T, Hotta A

Genetic correction using engineered nucleases for gene therapy applications. Development Growth & Differentiation, 2014; Vol.56 (1): p63-77.

Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S, Takahash J

Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate. Stem Cell Reports, 2013; Vol.1 (4): p283-292.

Yamashita A, Liu S, Woltjen K, Thomas B, Meng G, Hotta A, Takahashi K, Ellis J, Yamanaka S, Rancourt DE.

Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells. Scientific Reports, 2013; Vol.3: 1978.

Tanaka A, Woltjen K, Miyake K, Hotta A, Ikeya M, Yamamoto T, Nishino T, Shoji E, Sehara-Fujisawa A,Manabe Y, Fujii N, Hanaoka K, Era T, Yamashita S, Isobe K, Kimura E, Sakurai H.

Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi myopathy in vitro. PLoS ONE, 2013; Vol.8 (4): e61540.

Fussner E, Djuric U, Strauss M, Hotta A, Perez-Iratxeta C, Lanner F, Dilworth FJ, Ellis J, Bazett-Jones DP.

Constitutive heterochromatin reorganization during somatic cell reprogramming. EMBO Journal, 2011; Vol.30 (9): p1778-1789.

Kinoshita T, Nagamatsu G, Kosaka T, Takubo K, Hotta, A, Ellis J, Suda T.

Ataxia-telangiectasia mutated (ATM) deficiency decreases reprogramming efficiency and leads to genomic instability in iPS cells. Biochem Biophys Res Commun, 2011 Apr 8;407(2):321-6

Cheung AY, Horvath LM, Grafodatskaya D, Pasceri P, Weksberg R,Hotta, A, Carrel L, Ellis J.

Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X–chromosome inactivation. Hum Mol Genet, 2011; Vol 20 (11): p2103-2115.

Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, Ellis J, Keller G.

Stage-specific optimization of Activin/Nodal and BMP signaling promotes efficient cardiovascular differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell, 2011; Vol.8 (2): p228-240.

Hotta A, Cheung AY, Farra N, Garcha K, Chang WY, Pasceri P, Stanford WL, Ellis J.

EOS lentiviral vector selection system for human induced pluripotent stem cells. Nature Protocols, 2009; Vol.4 (12): p1828-1844.

Rastegar M, Hotta A, Pasceri P, Makarem M, Cheung AY, Elliott S, Park KJ, Adachi M, Jones FS, Clarke ID, Dirks P, Ellis J.

MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy. PLoS ONE, 2009; Vol.4 (8): e6810.

Hotta A, Cheung AY, Farra N, Vijayaragavan K, Seguin CA, Draper JS, Pasceri P, Maksakova IA, Mager DL, Rossant J, Bhatia M, Ellis J.

Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nature Methods, 2009; Vol.6 (5): p370-376.

Hotta A, Ellis J.

Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. J Cell Biochem, 2008; Vol.105 (4): p940-948.

Buzina A, Lo MY, Moffett A, Hotta A, Fussner E, Bharadwaj RR, Pasceri P, Garcia-Martinez JV, Bazett-Jones DP, Ellis J.

β-globin LCR and intron elements cooperate and direct spatial reorganization for gene therapy. PLoS Genet, 2008; Vol.4 (4): e1000051.

Ellis J, Hotta A, Rastegar M.

Retrovirus silencing by an epigenetic TRIM. Cell, 2007; Vol.131 (1): p13-14.

Morshed M, Ando M, Yamamoto J, Hotta A, Kaneoka H, Kojima J, Nishijima K, Kamihira M, Iijima S.

YY1 binds to regulatory element of chicken lysozyme and ovalbumin promoters. Cytotechnology, 2006; Vol.52 (3): p159-170.

Hotta A, Saito Y, Kyogoku K, Kawabe Y, Nishijima K, Kamihira M, Iijima S.

Characterization of transient expression system for retroviral vector production. J Biosci Bioeng, 2006; Vol.101 (4): p361-368.

Hotta A, Ono K, Mizuarai S, Yamaguchi K, Nishijima K, Kamihira M, Iijima S.

Production of pharmaceutical proteins by transgenic avian. Animal Cell Technology: Basic & Applied Aspects, 2004; Vol.13: p299-303.

Hotta A, Kamihira M, Itoh K, Morshed M, Kawabe Y, Ono K, Matsumoto H, Nishijima K, Iijima S.

Production of anti-CD2 chimeric antibody by recombinant animal cells. J Biosci Bioeng, 2004; Vol.98 (4): p298-303.

Ono K, Kamihira M, Kuga Y, Matsumoto H, Hotta A, Itoh T, Nishijima K, Nakamura N, Matsuda H, Iijima S.

Production of anti-prion scFv-Fc fusion proteins by recombinant animal cells. J Biosci Bioeng, 2003; Vol.95 (3): p231-238.
著作物

蒔田幸正, 穂積裕幸, 堀田秋津

筋ジストロフィー治療応用を目指したゲノム編集技術の開発動向 Clinical Calcium, 2017; Vol.27 (3): p67-75 (p391-399).

石田賢太郎, 徐 淮耕, 堀田秋津

第2章-8. ヒトでのゲノム編集 -遺伝子治療応用へと動き出した現状 実験医学増刊号 "All About ゲノム編集" 2016年 Vol.34 No.20 p133-140. 真下知士, 山本 卓 編

堀田秋津

iPS細胞におけるゲノム編集 学友会会誌 2016年 Vol.36 p45-48.

徐 淮耕, 堀田秋津

Duchenne型筋ジストロフィーに対するゲノム編集戦略 医学のあゆみ, 2016; Vol.259 (1): p73-79.

李 紅梅, 堀田秋津

第2章 ヒト人工多能性幹細胞(iPS細胞)でのゲノム編集 実験医学別冊 "論文だけではわからない ゲノム編集成功の秘訣Q&A" 2015年11月号; p96-105. 山本 卓 編

堀田秋津, 石田賢太郎, 佐伯涼太

疾患iPS細胞研究を加速する遺伝子改変技術の進歩 病理と臨床, 2015年6月号; Vol.33 (6): p622-626.

津下 到, 鈴木茂彦, 内藤素子, 堀田秋津, 井上治久

患者由来iPS細胞を用いた神経疾患研究 医学のあゆみ, 2015; Vol.252 (7): p824-828.

李 紅梅, 佐伯涼太, 堀田秋津

第5章 幹細胞技術開発「再生医療に向けたゲノム編集技術」 実験医学増刊 "再生医療2015 幹細胞と疾患iPS細胞の研究最前線" 2015; Vol.33 (2): p194 (346)-200 (352).
岡野 栄之, 山中 伸弥 編

Li, LH and Hotta, A.

Chapter 3: Editing Cultured Human Cells: From Cell Lines to iPS Cells Targeted Genome Editing Using Site-Specific Nucleases, Jan 14th 2015; p45-69,
Editor: Takashi Yamanoto

堀田秋津

iPS細胞応用を加速するゲノム編集技術 医学のあゆみ, 2015; Vol.252 (2): p183-188.

Hotta A, Yamanaka S

Chapter 2: Induced Pluripotent Stem Cells Biomaterials and Regenerative Medicine, Oct 2014; Editor, Peter Ma

李 紅梅, 堀田秋津

CRISPR/Casを用いた遺伝子治療への展望 実験医学, 2014; Vol.32 (11): p220-224.

堀田秋津

細胞種変換を支える遺伝子導入技術 細胞, 2014; Vol.46 (5): p220-224.

李 紅梅,佐久間哲史, 堀田秋津, 山本 卓

遺伝子改変法4:TALENによる遺伝子ターゲティング ES・iPS細胞実験スタンダード, 2014年3月5日発行, 監修:中辻憲夫, 編集:末盛博文

李 紅梅,Knut Woltjen,高橋和利,山中伸弥,堀田秋津

TALENを用いたヒトiPS細胞におけるゲノム編集 細胞工学, 2013; Vol.32 (5): p526-531.

堀田秋津

iPS細胞の小分子制御 学術の動向, 2011; Vol.16 (5): p62-65.

Sciabica, K, Woltjen, K, Hotta, A.

Multiplex gene-expression assay for human induced Pluripotent stem cells. Genetic Engineering & Biotechnology News (GEN), 2010; Vol.30 (3).

Kawabe Y, Hotta A, Ono K, Esaka K, Nishijima K, Kamihira M, Iijima S

Production of chimeric antibodies by transgenic chicken bioreactors. Animal Cell Technology: Basic & Applied Aspects, 2006; Vol.14: p309-315.

Hotta A, Saito K, Nishijima K, Kamihira M, Iijima S

Preparation of high-titer retroviral vectors using transient expression system. Animal Cell Technology: Basic & Applied Aspects, 2006; Vol.14: p293-299.

Hotta, A, Ono, K, Mizuarai, S, Yamaguchi, K, Nishijima, K, Kamihira, M, Iijima, S.

Production of pharmaceutical proteins by transgenic avian. Animal Cell Technology: Basic & Applied Aspects, 2004; Vol.13: p299-303.
go top